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Abstract 
Interleukin-1 receptor antagonist protein (IRAP) is a naturally occurring inhibitor of the interleukin-1 receptor. In contrast to IL-lb, IRAP binds 
to the IL-l receptor but does not elicit a physiological response. We have determined the solution structure of IRAP using NMR spectroscopy. While 
the overall topology of the two 153-residue proteins is quite similar, functionally critical differences exist concerning the residues of the linear amino 
acid sequence that constitute structurally homologous regions in the two proteins. Structurally homologous residues important for IL-l receptor 
binding are conserved between IRAP and IL-l/!?. By contrast, structurally homologous residues critical for receptor activation are not conserved 
between the two proteins. 
Key words: Interleukin-lp; Interleukin-1 receptor antagonist protein; Protein NMR spectroscopy; Isotopic enrichment 
1. Introduction 
Interleukin-l/? (IL-l/?) is a cytokine with inflamma- 
tory, immunological and pathological properties (for a 
review see [l]). The 17 kDa protein binds to two classes 
of IL-l receptors, resulting in the mediation of several 
immune and inflammatory responses and in the induc- 
tion of a variety of biological changes in neurologic, 
metabolic, hematologic, and endocrinologic systems [11. 
In addition to IL-l/?, an interleukin-1 receptor antago- 
nist protein (termed either IRAP or IL-lra) has been 
isolated, characterized, cloned and expressed in E. coli 
[2-4]. This newer member of the IL-l gene family is a 
naturally occurring inhibitor of the interleukin-1 recep- 
tor [2,4], and represents the first described naturally 
occurring cytokine that functions entirely as a specific 
receptor antagonist. 
Site-directed mutagenesis [5-lo] and protein modifica- 
tion [6,1 l] studies have identified regions of IL-l/? that 
are involved in either receptor binding or transmission 
of the biological response upon binding. For IRAP, it 
can be hypothesized that the regions of structure impor- 
tant for receptor binding are maintained, but that the 
region or regions responsible for eliciting the response 
are somehow different. To this end, we have determined 
the solution structure of IRAP using NMR spectros- 
copy. Since the structure of IL-l/? has already been deter- 
mined by X-ray crystallographic [ 12-141 and solution 
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NMR spectroscopy [15], a direct comparison between 
the structures of IRAP and IL-1B can be made. Correla- 
tions between structural and biological differences can 
now be understood at the molecular level. 
2. Materials and methods 
2.1. Protein 
Uniformly 15N- and “C/“N-enriched IRAP, a prerequisite for solu- 
tion structure determination, was prepared using a bacterial expression 
system as described previously [16]. Samples for NMR spectroscopy 
typically were 2 mM IRAP, 50 mM 2H,-ethanolamine and 300 mM 
NaCl at pH 6.4. Trace amounts of PMSF and NaN, were added to 
prevent any protease digestion or bacterial growth in the sample. All 
experiments were recorded at 300 K on a Bruker AMX-600 spec- 
trometer. 
2.2. NMR experiments 
A variety of NMR experiments were recorded on [“NjIRAP and/or 
[‘3C/‘SN]IRAP in order to make sequential resonance assignments, de- 
termine the solution secondary structure and provide for the extraction 
of structural constraints [l&18]. Experimental details and examples of 
the quality of the IRAP NMR spectra can be found in the references 
given. In addition to these experiments, two-dimensional ‘H-15N 
HMQC-J [19] and three-dimensional ‘H-“N HMQC-NOESY spectra 
were acquired. The HMQC-J data set was zero-filled four times for a 
final spectral resolution of 0.5 Hz/pt in the t, dimension. 3J,,, values, 
measured from peak splittings, were corrected for the effect of 
linewidth. The ‘H-“N HMQC-NOESY spectrum was acquired without 
“N decoupling in o,, allowing heteronuclear coupling constants to be 
extracted [20]. 
2.3. Structural constraints 
A total of 683 constraints were used in the calculations. Not including 
the unassigned ten residues of the N-terminus, this corresponds to 4.8 
constraints per residue. A total of 419 NOES, corresponding to inter- 
proton distances, were extracted from two-dimensional ‘H-‘H NOESY 
and three-dimensional ‘H-15N NOESY-HMQC spectra. The interpro- 
ton distance constraints were all inter-residue, and were derived from 
285 sequential, 21 medium-range (between protons of residues sepa- 
rated by 2-4 residues in the linear sequence) and 113 long-range (be- 
tween protons of residues z 4 residues apart in the linear sequence) 
NOES. Assigned NOES were classified as strong, medium or weak. 
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Corresponding upper bound constraints were 3.0 A, 4.0 A and 5.0 A. 
The lower bound constraints used in the calculations were the van der 
Waals contact radii. Although several hundred intra-residue NOES 
were also assigned, they were not incorporated into the structure calcu- 
lations since they provided little meaningful information. The 419 
NOE-derived distance constraints were supplemented with 96 distance 
constraints assigned to hydrogen bonds based on slowly exchanging 
amide protons [16]. All 96 distance restraints represented hydrogen 
bonds between adjacent /?-sheet strands. 
A total of 168 torsion angle constraints were also incorporated into 
the calculations, including 68 4 values extracted from the rH-15N 
HMQC-J spectrum, 70 yl values derived from ‘% chemical shifts [21] 
and three-bond “N(i)-‘Ha(i-1) coupling constants, and 30 xi values. 
$ values were constrained between -160” and -80” for 3Jn,, values 
>8 Hz. w values were constrained between 60” and 180” if one of 
the following conservative criteria was met: &J’%” must be less than 
-1.0 and zlS’%.? must be greater than 3.0; dS”C” must be less than 
-1.5 and &“Cfi must be greater than 2.0; or dS”C” must be less than 
-2.0 and dS r3Cs must be greater than 1.0. If only one part of a given 
dS13C criteria was met but the three-bond ‘5N(i)-‘Ha(i-l) coupling 
constant was less than 1 Hz, the y value was constrained between 
-20” and -100” (in a non-helical geometry). In two cases, the three- 
bond “N(i)-‘Ha(i-1) coupling constant was 4 Hz, allowing the yl value 
to be constrained between -120” and 0”. x, values were defined only 
when the three-bond “N(i)-‘H)(i) coupling constants in the ‘H-r5N 
HMQC-NOESY spectrum and the ‘Ha-‘HB correlations in the DQF- 
COSY spectrum were resolved. x, values were constrained to a f40” 
range. 
2.4. Structure calculations 
All structure calculations were run on a Silicon Graphics Iris Crim- 
son computer using the program DGII from Biosym Technologies Inc. 
Force constants used were 40 kcaYmol/A* for distance constraints and 
40 kcal/mol/rad’ for torsion angle constraints, An initial energy of 6,000 
kcal/mol and a time step of 0.4 ps gave convergence for 13 out of 20 
structures calculated using a final DGII error of less than 2.00 as the 
acceptable criteria. The program Discover from Biosym Technologies 
Inc. was then used to reduce repulsive non-bonded contacts, Each of 
the 13 DGII structures was subjected to restrained energy minimization 
using 100 iterations of steepest descents and 1000 iterations of conju- 
gate gradients. These 13 structures have been deposited in the 
Brookhaven Protein Data Bank. For the 13 structures, residual NOE 
and distance restraint violations are small, with no violations greater 
than 0.5 A in any structure. The number of violations above 0.3 A is 
1.5 f 0.7 per structure. Dihedral angle restraint violations were also 
minimal, with no violations greater than 15” for any structure. For 
comparison with the NMR solution structure of IL-l/3, the average of 
these 13 structures was calculated and subjected to restrained energy 
minimization as described above. Since the 10 N-terminal residues have 
not been assigned and have had no constraints imposed on them, they 
are not included in any of the figures nor in any of the structural 
statistics given. 
Fig. 1. (A) Stereoview of the superimposed backbone N, C” and C’ atoms for the 13 calculated structures of IRAP. For alignment, the residue ranges 
used were 12-27,3&34,4652,5684, lot%136 and 147-152. (B) Stereoview of the overlay of the backbone N, C” and C’ atoms of IRAP (thick line) 
and IL-l/l (thin line). The IRAP structure is numbered every 10 residues. Alignment is based on corresponding b-strands between the two protein: 
residues 12-27, 3&34, 4652, 5684, 100-136 and 147-152 for IRAP and residues 6-21, 25-29,41-47, 57-85, 100-136 and 146151 for IL-lp. The 
IL-lb structure used is that contained in the Brookhaven Protein Data Bank file 6ilb. 
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Fig. 2. Ribbon diagram of the average structure of IRAP in the same orientation as in Fig. 1. The B-strands are labeled with Roman numerals. Side 
chains of residues defined bv mutagenesis to be imnortant for receutor binding (grey) and response elicitation (black) are shown. This figure was 
generated using the program MOLSCRIPT [24]. _ 
3. Results and discussion 
An overlay of the final 13 IRAP structures is shown 
in Fig. 1A. The average RMS deviation to the average 
structure for all heavy atoms is 2.77 f 0.19 A and for the 
backbone N, C” and C’ atoms is 2.03 + 0.18 A. The 
structures shown in Fig. 1A have been superimposed 
based on the best fit alignment of only residues in the 
well-defined B-sheet framework of each protein (100 out 
of the 143 residues). Considering just these residues, the 
average RMS deviation to the average structure for all 
heavy atoms is 2.36 f 0.20 8, and for the backbone N, 
C” and C’ atoms is 1.67 + 0.18 A. As is clear from Fig. 
lA, the/I-sheet strands are much better defined than the 
loop regions of IRAP. The topology of the B-sheet 
strands is more clearly seen in the ribbon diagram of 
the average IRAP structure shown in Fig. 2. The 12 
B-strands are arranged in the same B-trefoil fold topol- 
ogy [22] observed for IL-l/? [15,23]. This topology con- 
sists of six two-stranded hairpins, three of which form a 
six-stranded/?-barrel (strands XII-I, IV-V and VIII-IX) 
and three of which cap the barrel (strands II-III, VI-VII 
and X-XI). 
The high level of structural homology between IRAP 
and IL-l/I is apparent from Fig. lB, which shows an 
overlay of the backbone atoms of the two proteins. The 
alignment is based on homologous B-strands as defined 
previously [16,17]. For this subset of 100 residues, the 
RMS deviation between the two proteins for the back- 
bone N, C” and C’ atoms is 2.27 A. While the overall 
topology of the two 153-residue proteins is quite similar, 
several functionally critical differences exist concerning 
the residues of the linear amino acid sequence that con- 
stitute structurally homologous regions in the two pro- 
teins. The largest differences are at the N-terminus, 
where the first six residues of IRAP have no structural 
counterpart in IL-lp, and in the 50’s region, where IL-l/? 
has a five-residue insertion beginning at residue 50. Two 
additional differences, defined on the basis of C” coordi- 
nates, are a deletion in IRAP corresponding to residue 
24 in IL-l/? and a deletion in IL-1s corresponding to 
residue 142 in IRAP. A third deletion occurs in the 90’s 
region of IL-l@. The exact location cannot be determined 
because this loop region is poorly defined in the IRAP 
NMR structure. 
The structure of IRAP presented here allows compar- 
isons to be made with the solution structure determined 
previously for IL-lp [15]. While both proteins bind the 
IL-l receptor with the same affinity, only the binding of 
IL-l/I causes activation. A comparison of the two pro- 
teins, in the context of site-directed mutagenesis data, 
provides a basis for understanding the structure- 
function relationships at the molecular level that underlie 
the different physiological effects of the two proteins. A 
summary of residues required for binding or receptor 
activation as defined by single-site mutants, deletions or 
loop substitutions [5-lo] and chemical modification 
[6,1 l] is shown in Fig. 2. The IRAP residues shown 
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Fig. 3. Stereoview of the overlay of B-strands I and XII of IRAP (thick lines) and IL-l/3 (thin lines). Alignment is based the backbone N, C” and 
C’ atoms of residues 12-18 and 145-152 of IRAP with residues cl2 and 144-151 of IL-1B. Only heavy atoms are shown for the side chains, which 
differ between the two proteins 
correspond structurally to those residues in IL-l/? that 
have been found to be required for binding or activation. 
The majority of the residues important for receptor 
binding are clustered on one side of the protein encom- 
passing residues 88-105. Residues 12 and 16, located on 
one side of the N-terminal B-strand, and residue 55 are 
also involved in receptor binding and are located near 
the 88-105 region. The hydrophobic or hydrophilic na- 
ture of these residues are highly conserved between 
IRAP and IL-1B providing a rationale for the ability of 
both proteins to bind to the IL-l receptor. 
Residues T9, Rll and D145 have been defined by 
site-directed mutagenesis of IL-l/? to be critical for recep- 
tor activation without effecting receptor binding. The 
structurally homologous residues in IRAP are R 15, W 17 
and K146. These three residues are located on one face 
of IRAP as shown in Fig. 2. R15 and W17 are on the 
same side of the N-terminal/?-strand and K146 is located 
on an adjacent /?-strand. An overlay of these two 
B-strands in IRAP and IL-lp is shown in Fig. 3. The 
RMS deviation for the backbone N, C” and C’ atoms is 
1.15 A. The orientation of these three side chains with 
respect to a potential receptor interactions site is very 
similar between the antagonist and agonist proteins. The 
lack of conservation between IRAP and IL-l/I at these 
positions, in contrast to what is observed for the struc- 
turally homologous receptor-binding residues, is likely 
to be responsible for the difference in activity between 
the two proteins. 
The structurally homologous IRAP K146 and IL-la 
D145 residues hown in Fig. 3 may be especially critical, 
as they seem to comprise an antagonist/agonist witch. 
In addition to a D145K mutation in IL-la, effectively 
making the agonist IRAP-like at this position, losing the 
ability to activate the receptor, a K146D mutation in 
IRAP, effectively making the antagonist IL-l/?-like at 
this position, has been shown to make IRAP into a re- 
ceptor agonist, albeit a weak one [8]. 
The solution structure or IRAP presented here com- 
plements the previously determined structure of IL-1B. 
Together they provide a framework to interpret mut- 
agenesis data and suggest potential mutations that might 
be made to further define the critical regions of the two 
proteins. The structure suggests that the 88-105 loop of 
IRAP may be a useful target in the design of small mol- 
ecules that may mimic IRAP’s role as a receptor antago- 
nist. This approach may be limited by the fact that this 
region is not well defined in the structure (Fig. 1A). This 
is attributed to a smaller number of assigned NOES for 
these residues. In addition, the resonances arising from 
residues in this region are weak or missing, suggesting 
conformational heterogeneity. A potential solution may 
be to determine the conformation as it is bound to the 
receptor, perhaps by forming a complex between 
[‘3C,‘5N]IRAP and unlabeled receptor. This may lead to 
the development of small molecules that contain similar 
functional groups constrained in the same conformation 
as found in this region of IRAP. 
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